Summit Therapeutics
SMMT
11 hedge funds and large institutions have $3.37M invested in Summit Therapeutics in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0.04% more ownership
Funds ownership: 1.62% → 1.66% (+0.04%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
27% less funds holding
Funds holding: 15 → 11 (-4)
29% less capital invested
Capital invested by funds: $4.75M → $3.37M (-$1.38M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| 1 |
Bank of New York Mellon
New York
|
+$198K |
| 2 |
Morgan Stanley
New York
|
+$27.2K |
| 3 |
Renaissance Technologies
New York
|
+$13.7K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPU
1
Lansdowne Partners (UK)
London,
United Kingdom
| $2.02M | – | – | – |
|
|
PC
2
Polar Capital
London,
United Kingdom
| $436K | -$8.9K | -5,319 | -2% |
|
|
3
Morgan Stanley
New York
| $309K | +$27.2K | +16,245 | +7% |
|
|
4
Bank of New York Mellon
New York
| $274K | +$198K | +118,501 | +120% |
|
5
Acadian Asset Management
Boston,
Massachusetts
| $220K | -$3.54K | -2,115 | -1% |
|
|
6
Renaissance Technologies
New York
| $107K | +$13.7K | +8,200 | +11% |
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | -$16.1K | -9,600 | -83% |
|
8
Group One Trading
Chicago,
Illinois
| $1K | – | – | – |
|
|
LFG
9
Larson Financial Group
St Louis,
Missouri
| $1K | – | – | – |
|
|
PFBT
10
Parkside Financial Bank & Trust
Saint Louis,
Missouri
| $1K | – | – | – |
|
11
Citadel Advisors
Miami,
Florida
| – | -$44K | -23,783 | Closed |
|
|
SWM
12
SeaCrest Wealth Management
Purchase,
New York
| – | -$41K | -22,322 | Closed |
|
|
VF
13
Virtu Financial
New York
| – | -$20K | -10,751 | Closed |
|
SMMT Hedge Fund Activity: Q2 2019 in Review
11 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2019, worth a combined $3.37M — down 29% from $4.75M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SMMT and 0 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Bank of New York Mellon, adding an estimated $198K. The largest seller was Citadel Advisors, exiting entirely with an estimated $44K sold.
- 11 institutional investors held Summit Therapeutics (SMMT) as of Q2 2019, down from 15 in Q1 2019.
- Funds reported $3.37M of Summit Therapeutics stock for Q2 2019, down 29% quarter-over-quarter.
- 0 funds opened new Summit Therapeutics positions in Q2 2019 and 4 closed out, a net change of -4 holders.
- The largest Summit Therapeutics buyer in Q2 2019 was Bank of New York Mellon, an estimated $198K added.
- The largest Summit Therapeutics seller in Q2 2019 was Citadel Advisors, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2019.